Navigation Links
Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors
Date:6/11/2008

DANBURY, Conn., June 11 /PRNewswire-FirstCall/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Barry Ginsberg, M.D., Ph.D., has been elected as a new member of its Board of Directors, effective June 10, 2008. Dr. Ginsberg is currently Chief Executive Officer of Diabetes Technology Consultants where he advises Fortune 500 companies in the field of diabetes.

"We are pleased to welcome Barry to our Board of Directors at such an important time for Biodel," stated Dr. Solomon Steiner, Chief Executive Officer and Chairman of Biodel. "Barry's diabetes expertise and experience as a seasoned advisor to commercial stage companies will provide invaluable insights and contributions to Biodel as we prepare to file VIAject(TM)'s New Drug Application by the end of 2008."

Dr. Ginsberg joins the Company's Board of Directors with over 25 years of experience in diabetes. Prior to Diabetes Technology Consultants, Dr. Ginsberg served as Vice President of Worldwide Medical Affairs in the Diabetes HealthCare Division at Becton Dickinson during his 17 year tenure. Dr. Ginsberg currently serves as Chairman of the Scientific Advisory Boards at Agamatrix and Therafuse, and is a Scientific Advisory Board Member at Covidien, Metacure, Glucolight and Becton Dickinson Diabetes HealthCare. While a Professor of Medicine at the University of Iowa (1977-90), he was a Principal Investigator of the prestigious Diabetes Control and Complications Trial.

Biodel also announced that Albert Cha, M.D., Ph.D. will depart from the Company's Board of Directors. Dr. Cha, a Managing Partner of Vivo Ventures, joined the Company's Board of Directors in July 2006.

"Albert has been a valued source of counsel and he served our Company and its shareholders well during our transition from an early stage private company to a public company with a late stage Phase III product candidate. We thank him for his service and wish him well," stated Dr. Steiner.

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel's product candidates are developed by using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs. The Company's lead product candidate, VIAject(TM), is an ultra rapid-acting injectable meal-time insulin in development for use by patients with Type 1 or Type 2 diabetes. VIAject(TM) is currently being tested in two pivotal Phase III clinical trials. Biodel's pipeline also includes VIAtab(TM), a sublingual tablet formulation of insulin in the Phase I stage of clinical testing, and two pre-clinical osteoporosis product candidates. For further information regarding Biodel, please visit the Company's website at http://www.biodel.com.

BIOD-G


'/>"/>
SOURCE Biodel Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Escalon(R) Announces Promotion of Industry Veteran Barry Durante to President of Sonomed, Inc.
2. MacAndrews & Forbes Names Barry F. Schwartz as Executive Vice Chairman
3. Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer
4. David S. Tierney, M.D., Joins Thomas, McNerney & Partners as Entrepreneur-In-Residence
5. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
6. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
7. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
8. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
9. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
10. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
11. Cynthia Haines, M.D., Named Managing Editor of Physicians Briefing News Wire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... -- On Thursday, February 11, 2-1-1 San Diego ... and disaster services, and the Community Information Exchange ... coordination and service delivery for the community to better ... better connect service providers to the information they can ... has handled more than 2.5 million connections ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... 4, 2016 Beike Biotechnology, the ... attended a ceremony in late 2015 to mark their ... in 2016. --> --> ... for Personalized Cell Therapy" was hosted by the Shenzhen ... both subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... -- ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ), a ... targeted antiviral therapies, announced today that it will present ... held February 8-9, 2016, at the Waldorf Astoria New ... Healthcare Conference, taking place in New York ... Sapirstein , Chief Executive Officer of ContraVir, will provide ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016   Parabon NanoLabs (Parabon) ... Army Research Office and the Defense Forensics and ... of the company,s Snapshot Kinship Inference ... more generally, defense-related DNA forensics.  Although Snapshot is ... appearance and ancestry from DNA evidence), it also ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
(Date:1/27/2016)... Jan. 27, 2016  Rite Track, Inc. a leading ... West Chester, Ohio announced today the ... staff, based in Austin, Texas , ... to provide modifications, installations and technical support offerings for ... of PLUS, commented, "PLUS has provided world class service ...
Breaking Biology News(10 mins):